Introduction Many middle-income countries such as Egypt, South Africa, Malaysia, Thailand, and Brazil have pharmacoeconomic guidelines. These follow the recommendations by the International Society for Pharmacoeconomics and Outcomes Research but include country-specific differences. The variations respond to changes in how governments apply pharmacoeconomics and determine market access to pharmaceuticals and medical devices. This is also […]
Read all
Introduction The market access landscape in the Middle East and North Africa (MENA) is dynamic and rapidly changing. MENA is diverse, comprising many dissimilar countries, with different cultures, including languages, used in commerce. The concerns about the long-term sustainability of oil revenues are driving to shape healthcare markets. There are different approaches to regulating healthcare […]
Read all
What is Budget Impact Analysis? Pharmacoeconomic analyses in healthcare are paramount, because of the high costs of innovative technologies and limited possibilities of their funding. Budget Impact Analysis (BIA) is one such analysis that provides vital information for healthcare decision makers. [1] Unlike economic evaluations, such as cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit […]
Read all